Patent SG-11201907451X-A (SG)
Title: Substituted imidazo-quinolines as nlrp3 modulators
Inventor: GLICK GARY
IPC: A61P37/00
Filed: 2018-02-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIPO I PCT omit VIII °nolo HE oimIE (10) International Publication Number WO 2018/152396 Al N NR 1 R 2 ) ( R 6 N R 7 R 3 W O 20 18/ 15 2396 Al (51) International Patent Classification: CO7D 471/04 (2006.01) A61P 37/00 (2006.01) A61P 35/00 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/US2018/018484 (22) International Filing Date: 16 February 2018 (16.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/460,677 17 February 2017 (17.02.2017) US 62/490,881 27 April 2017 (27.04.2017) US 62/573,991 18 October 2017 (18.10.2017) US (71) Applicant: INNATE TUMOR IMMUNITY, INC. [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (72) Inventors: GLICK, Gary; c/o Innate Tumor Immunity, Inc., Route 206 & Province Line Road, Princeton, New Jer- sey 08543 (US). GHOSH, Shomir; c/o Innate Tumor Im- munity, Inc., Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). ROUSH, William R.; c/o Innate Tumor Immunity, Inc., Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). OLHAVA, Edward James; c/o Innate Tumor Immunity, Inc., Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). O'MALLEY, Daniel; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (74) Agent: SUN, Jing G. et al.; Bristol-Myers Squibb Compa- ny, Route 206 & Province Line Road, Princeton, New Jer- sey 08543 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) = (54) Title: SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS NH 2 (57) : This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/ or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/ or symptoms and/ or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.